1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Another World-First As Japan OKs Spinal Injury Cell Therapy Trial

 
• By Ian Haydock

In another globally pioneering move, Japan approves a trial with its flagship iPS cell technology in spinal cord injury, following a controversial earlier marketing approval in the same indication.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery.
Japan iPSC Trial Aims To Regenerate Neurons • Source: Shutterstock

Despite controversy over a recent pioneering marketing approval of a cell-based therapy for spinal cord injury, Japan has taken another world-leading step in this arena as it looks to build a global leadership position.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.